Literature DB >> 12152163

Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.

Steffen Hauptmann1, Carsten Denkert, Ines Koch, Simone Petersen, Karsten Schlüns, Angela Reles, Manfred Dietel, Iver Petersen.   

Abstract

The genetic changes involved in the pathogenesis of ovarian carcinoma are not completely understood. To investigate this matter, we studied paraffin-embedded, microdissected tissue of 47 ovarian epithelial tumors (9 adenomas, 11 tumors of low malignant potential [LMP], 14 serous carcinomas, and 13 nonserous carcinomas) using comparative genomic hybridization (CGH). (The primary data used in this study are available at our CGH online tumor database at http://amba.charite.de/cgh.) Chromosomal imbalances were found in 1 serous adenoma and in 7 LMP tumors. In the latter the alterations appeared randomly and showed no overlap with alterations found in invasive carcinomas. Although the mean aberration number of low-grade serous carcinomas was comparable to LMP tumors, the imbalances of the former occurred with high incidence (>50%) and were found at different localizations. High-grade serous carcinomas had more than twice as much chromosomal imbalances as low-grade serous carcinomas and also had pronounced alterations. In serous carcinomas, gains were found on 3q, 6p, 7, 8q, and 20, and losses were found on 4q, 6q, 12q, 13q, and 16q. Comparing serous and nonserous carcinomas, the mean aberration number was comparable, but the number of high incidence changes was lower, and the most frequent imbalances were losses on 13q and gains on 20p. Overlapping alterations occurring in serous and nonserous carcinomas were gains on 3q and 6p, as well as losses on 4q. Chromosomal imbalances associated with poor prognosis of ovarian carcinomas were gains on 6p, 7q, and 13q and losses on 15q, 17p, 18q, and 21q. Our data indicate that serous LMP tumors and invasive carcinomas have different genetic aberrations, indicating that invasive carcinomas do not arise from preexisting serous LMP tumors. On the other hand, there are common genetic abnormalities in serous and nonserous carcinomas, suggesting that they have very early lesions in common but take different paths of further development. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12152163     DOI: 10.1053/hupa.2002.124913

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

Review 1.  Chromosome 6p amplification and cancer progression.

Authors:  Gda C Santos; M Zielenska; M Prasad; J A Squire
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

2.  Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

Authors:  Rebecca L Stone; Keith A Baggerly; Guillermo N Armaiz-Pena; Yu Kang; Angela M Sanguino; Duangmani Thanapprapasr; Heather J Dalton; Justin Bottsford-Miller; Behrouz Zand; Rehan Akbani; Lixia Diao; Alpa M Nick; Koen DeGeest; Gabriel Lopez-Berestein; Robert L Coleman; Susan Lutgendorf; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2014-04-23       Impact factor: 4.742

3.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Authors:  Kimberly J Bussey; Koei Chin; Samir Lababidi; Mark Reimers; William C Reinhold; Wen-Lin Kuo; Fuad Gwadry; Hosein Kouros-Mehr; Jane Fridlyand; Ajay Jain; Colin Collins; Satoshi Nishizuka; Giovanni Tonon; Anna Roschke; Kristen Gehlhaus; Ilan Kirsch; Dominic A Scudiero; Joe W Gray; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

4.  Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.

Authors:  Joachim Woenckhaus; Klaus Steger; Klaus Sturm; Karsten Münstedt; Folker E Franke; Irina Fenic
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

5.  Genomic aberrations in borderline ovarian tumors.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Hege K Andersen; Vera M Abeler; Ben Davidson; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Transl Med       Date:  2010-02-26       Impact factor: 5.531

6.  FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer.

Authors:  Elsa De La Chesnaye; Juan Pablo Méndez; Ricardo López-Romero; María De Los Angeles Romero-Tlalolini; María Dolores Vergara; Mauricio Salcedo; Sergio R Ojeda
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 7.  Large-scale genomic analysis of ovarian carcinomas.

Authors:  Kylie L Gorringe; Ian G Campbell
Journal:  Mol Oncol       Date:  2008-12-24       Impact factor: 6.603

Review 8.  Advanced molecular cytogenetics in human and mouse.

Authors:  Kathleen Dorritie; Cristina Montagna; Michael J Difilippantonio; Thomas Ried
Journal:  Expert Rev Mol Diagn       Date:  2004-09       Impact factor: 5.225

9.  Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.

Authors:  Manohar Pradhan; Ben Davidson; Claes Göran Tropé; Håvard Emil Danielsen; Vera Maria Abeler; Björn Risberg
Journal:  Virchows Arch       Date:  2009-05-08       Impact factor: 4.064

10.  Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.

Authors:  C A Barton; B S Gloss; W Qu; A L Statham; N F Hacker; R L Sutherland; S J Clark; P M O'Brien
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.